Please login to the form below
Quell Therapeutics
This page shows the latest Quell Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Syncona start-up Quell Therapeutics appoints chief exec
Biotech focusing on Tregs. Quell Therapeutics, a new UK biotech company focused on developing engineered T regulatory (Treg) cell therapies, has appointed Iain McGill as its chief executive. ... London-based Quell Therapeutics aims to harness this
Latest news
-
Syncona launches another cell therapy company, Treg specialist Quell
Focuses on novel immune system approach. Syncona has invested £34m ($43m) in start-up financing for Quell Therapeutics, a cell therapy company focusing on using T regulatory (Treg) cells to treat ... Another of its start-ups, gene therapy specialist
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Humancomms for humancare?
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
